WAKAMOTO PHARMACEUTICAL (4512) FY2026 Q3 Earnings Report

Financial Highlights

Item	Current	Prior	YoY %
Net Sales	¥7.31B	¥5.81B	+25.9%
Cost of Sales	¥3.80B	¥3.11B	+22.3%
Gross Profit	¥3.51B	¥2.70B	+30.0%
SG&A Expenses	¥3.32B	¥3.04B	+9.2%
Operating Income	¥187M	−¥341M	+154.8%
Non-operating Income	¥61M	¥59M	+4.1%
Non-operating Expenses	¥26M	¥14M	+82.0%
Ordinary Income	¥222M	−¥297M	+174.7%
Profit Before Tax	¥223M	−¥130M	+271.1%
Income Tax Expense	¥8M	−¥111M	+106.8%
Net Income	¥215M	−¥19M	+1231.6%
Interest Expense	¥745,000	¥557,000	+33.8%
Basic EPS	¥6.19	−¥0.55	+1225.5%

Item	Current End	Prior End	Change
Current Assets	¥9.02B	¥8.91B	+¥109M
Cash and Deposits	¥1.67B	¥2.95B	−¥1.28B
Accounts Receivable	¥3.55B	¥2.58B	+¥978M
Inventories	¥2.19B	¥1.96B	+¥229M
Non-current Assets	¥6.82B	¥6.09B	+¥728M
Property, Plant & Equipment	¥3.50B	¥3.31B	+¥188M
Intangible Assets	¥261M	¥278M	−¥17M
Investment Securities	¥2.39B	¥1.85B	+¥543M
Total Assets	¥15.84B	¥15.00B	+¥838M
Current Liabilities	¥2.25B	¥2.03B	+¥218M
Accounts Payable	¥789M	¥941M	−¥152M
Short-term Loans	¥100M	¥100M	¥0
Non-current Liabilities	¥1.50B	¥1.36B	+¥139M
Total Liabilities	¥3.75B	¥3.39B	+¥357M
Total Equity	¥12.09B	¥11.61B	+¥481M
Capital Stock	¥3.40B	¥3.40B	¥0
Capital Surplus	¥2.68B	¥2.68B	¥0
Retained Earnings	¥4.78B	¥4.67B	+¥111M
Treasury Stock	−¥37M	−¥36M	−¥103,000
Owners' Equity	¥12.09B	¥11.61B	+¥481M
Working Capital	¥6.77B	-	-

Item	YoY Change
Net Sales YoY Change	+25.9%

Item	Value
Shares Outstanding (incl. Treasury)	34.84M shares
Treasury Stock	132K shares
Average Shares Outstanding	34.71M shares
Book Value Per Share	¥348.38

Item	Amount
Q2 Dividend	¥0.00

Segment	Revenue	Operating Income
EthicalProductsBusinessRelated	¥3.46B	−¥548M
GlobalSalesDevelopmentBusinessRelated	¥1.79B	¥407M
OtcProductsBusinessRelated	¥1.92B	¥280M
RealEstateRental	¥140M	¥48M